FDA accepted NDA resubmission for Aldeyra Therapeutics, Inc., amid market reactions and speculation regarding tariff benefits for AI stocks.
1 report, 1 independent
Updated Aug 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA accepted NDA resubmission for Aldeyra Therapeutics, Inc., amid market reactions and speculation regarding tariff benefits for AI stocks.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
AbbVie (Netherlands)
company in Zwolle, Netherlands
Nothing else this week.
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
Coverage
Newest first; wire copies grouped- Insider MonkeyJonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is among the best US stocks under $10 to invest in. Catherine Novack, an analyst at Jo